Kallikrein 11 anticorps (AA 68-82)

N° du produit ABIN1736153

Détail du produit anti-Kallikrein 11 anticorps

Antigène: Kallikrein 11 (KLK11)

Épitope: AA 68-82

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Kallikrein 11 est non-conjugé

Application: Western Blotting (WB)

Specificité: Reacts with human Hippostasin/KLK11

Purification: Antigen affinity purified

Immunogène: Residues 68-82 [YIVHLGQHNLQKEEG] of the 35 kDa human hippostasin/KLK11protein. Sequence identity to mouse and rat: 86%.

Isotype: IgG

Information d'application

Indications d'application:

Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only:
- WB : 1/500 to 1/1 000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS, Sodium azide 0.02 %

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.

Date de péremption: 6 months

Détails sur Kallikrein 11

Antigène: Kallikrein 11 (KLK11)

Autre désignation: Kallikrein-11 (KLK11 Produits)

Synonymes: anticorps KLK11, anticorps 2310015I08Rik, anticorps Prss20, anticorps TLSP, anticorps PRSS20, anticorps kallikrein related peptidase 11, anticorps kallikrein related-peptidase 11, anticorps kallikrein-related peptidase 11, anticorps KLK11, anticorps Klk11

Sujet: Hippostasin, also known as KLK11, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type.Hippostasin plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of hK11 were found in 70 % of women with ovarian cancer and in 60 % of men with prostate cancer. Analysis of the KLK11 biomarker in serum may aid in the diagnosis and monitoring of ovarian and prostatic carcinoma.

Pathways: Système du Complément